JAN ALTISER: Open Payments
NPI 1336478601 · TRENTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,009 in 50 payments from 10 companies in 2025. Trend: 2023 $771 · 2024 $1,003 · 2025 $1,009
Food & beverage: $1,009
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 7 | $174 |
| E.R. Squibb & Sons, L.L.C. | 10 | $169 |
| Otsuka America Pharmaceutical, Inc. | 12 | $165 |
| Alkermes, Inc. | 6 | $151 |
| Neurocrine BioSciences, Inc. | 5 | $149 |
| Janssen Pharmaceuticals, Inc | 2 | $55 |
| Lundbeck LLC | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| ABBVIE INC. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
Products named: COBENFY, INGREZZA, ARISTADA, FANAPT, REXULTI, ABILIFY ASIMTUFII, INVEGA SUSTENNA, HETLIOZ.
Industry payments across MO — which companies pay providers there.
